Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

572
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
572
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

351
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
351
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

388
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
388
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

695
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
695
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.2K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib.

Clinical and experimental dermatology·2021
Same author

[Pulmonary involvement in rheumatoid arthritis].

Zeitschrift fur Rheumatologie·2019
Same author

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Zeitschrift fur Rheumatologie·2018
Same author

[Recommendations on the use of rituximab for ANCA-associated vasculitis].

Zeitschrift fur Rheumatologie·2016
Same author

[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].

Zeitschrift fur Rheumatologie·2016
Same author

[Do we still need clinical studies in rheumatology?].

Zeitschrift fur Rheumatologie·2015
Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026
Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026
Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026
Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026
Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026
Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026
See all related articles

Related Experiment Video

Updated: Feb 15, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

[Lymphoma in rheumatic diseases].

A Rubbert-Roth1, J T Bittenbring2, G Assmann2

  • 1Medizinische Klinik I der Universität Köln, Joseph-Stelzmann Str. 9, 50924, Köln, Deutschland. andrea.rubbert@uk-koeln.de.

Zeitschrift Fur Rheumatologie
|January 14, 2018
PubMed
Summary
This summary is machine-generated.

Systemic inflammatory diseases like rheumatoid arthritis increase lymphoma risk, particularly with higher disease activity. Current treatments show no increased lymphoma risk, but managing patients with prior lymphoma requires individualized, interdisciplinary care.

Keywords:
BiologicsDMARDsRheumatoid arthritisSjogren’s syndromeSystemic lupus erythematosus

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

852
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.9K

Related Experiment Videos

Last Updated: Feb 15, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

852
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.9K

Area of Science:

  • Rheumatology
  • Oncology
  • Immunology

Background:

  • Systemic inflammatory diseases, including rheumatoid arthritis (RA), Sjögren's syndrome, and systemic lupus erythematosus (SLE), are linked to a higher incidence of lymphomas.
  • Lymphoma development in RA and Sjögren's syndrome correlates with disease severity and activity, often occurring in immunosuppressed individuals.

Purpose of the Study:

  • To inform rheumatologists about lymphoma subtypes, prognoses, and treatment options in the context of systemic inflammatory diseases.
  • To address the complexities of treating patients with a history of lymphoma who require antirheumatic therapies.

Main Methods:

  • Review of existing literature on lymphoma risk in patients with systemic inflammatory diseases.
  • Analysis of current evidence regarding the impact of conventional and biologic disease-modifying antirheumatic drugs (DMARDs) on lymphoma risk.
  • Consideration of challenges in managing patients with prior malignancies.

Main Results:

  • No evidence suggests an increased lymphoma risk associated with current conventional or biologic DMARDs.
  • Lymphoma incidence is associated with increased severity and activity of underlying inflammatory diseases.
  • Treatment decisions for patients with prior lymphoma and inflammatory conditions are complex due to limited clinical study data.

Conclusions:

  • Rheumatologists need comprehensive knowledge of lymphoma subtypes, prognosis, and treatment.
  • Individualized and interdisciplinary management, involving hematologists, is crucial for patients with a history of lymphoma requiring antirheumatic treatment.
  • Current DMARDs do not appear to elevate lymphoma risk in patients with systemic inflammatory diseases.